The only remaining risk is the USPTO. IMO not much risk, since we are taling 4 patents not 1. But the level of uncertainty depends on whether the PTSC investor has read the reexam responses to the 584 and 148. Knowing what is contained in those responses, and understanding the technology behind the 336 vs prior art determines what each individual sees as risk. How many shareholders have done that? Therein perhaps lies a problem. And therein perhaps lies huge opportunity for some. All IMHO Opty